NDA 020080 · Glaxosmithkline
Imitrex Statdose (Autoinjector)
Sumatriptan Succinate · Subcutaneous
NovelPriority reviewLast checked: Nov 19, 2026Latest source record: Dec 9, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1992
Dec 28, 1992
Approved uses
3
Original approval plus efficacy supplements
Registered trials
113
33 Phase 3, 5 recruiting
FAERS reports
38,243
19,164 serious, 909 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 9, 2025.
IMITREX injection is indicated in adults for (1) the acute treatment of migraine, with or without aura, and (2) the acute treatment of cluster headache. Limitations of Use • Use only if a clear diagnosis of migraine or cluster headache has been established. If a patient has no response to the first migraine or cluster headache attack treated with IMITREX injection, reconsider the diagnosis before IMITREX injection is administered to treat any subsequent attacks. • IMITREX injection is not indicated for the prevention of migraine or cluster headache attacks. IMITREX injection is a serotonin (5-HT 1B/1D ) receptor agonist (triptan) indicated for: • Acute treatment of migraine with or without aura in adults. ( 1 ) • Acute treatment of cluster headache in adults. ( 1 ) Limitations of Use • Use only if a clear diagnosis of migraine or cluster headache has been established. ( 1 ) • Not indicated for the prophylactic therapy of migraine or cluster headache attacks. ( 1 )
Mechanism: Sumatriptan binds with high affinity to human cloned 5-HT 1B / 1D receptors. Sumatriptan presumably exerts its therapeutic effects in the treatment of migraine and cluster headaches through agonist effects at the 5-HT 1B / 1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro‑inflammatory neuropeptide release.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 1, 2006 Supplement 36 · Efficacy LabelLetter
- May 22, 1996 Supplement 4 · Efficacy
- Dec 28, 1992 Original approval · Type 1 - New Molecular Entity · priority review Other Important Information from FDA
3 products under this application
- IMITREX STATDOSE (AUTOINJECTOR) · SUMATRIPTAN SUCCINATE EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AB
- IMITREX STATDOSE (AUTOINJECTOR) · SUMATRIPTAN SUCCINATE EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription · TE AB
- IMITREX · SUMATRIPTAN SUCCINATE EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, SUBCUTANEOUS · Discontinued · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Sumatriptan" as an intervention, any sponsor and status, largest first.
- Quality Improvement and Practice Based Research in Neurology Using the EMREnrolling by invitation
Endeavor HealthAcademic, hospital or other
NCT02670161 · 3,300 participants (planned) · Start May 2016 · Primary completion Dec 2026
Drug: Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description) · For: Brain Tumors; Epilepsy; Migraine and 7 more
Sites: Evanston, Illinois
- To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migraine HeadachesPivotal-lookingCompleted
POZENIndustry
NCT00433732 · 1,400 participants · Start Aug 2004
Drug: sumatriptan; naproxen sodium · For: Migraine Headaches
Sites: Little Rock, Arkansas; Chapel Hill, North Carolina
- Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00898677 · 1,268 participants · Start Sep 1995 · Primary completion May 1996
Drug: rizatriptan benzoate; rizatriptan benzoate and 2 more · For: Migraine Headache
- To Evaluate the Safety and Efficacy of Trexima in the Acute Treatment of Migrane HeadachesPivotal-lookingCompleted
POZENIndustry
NCT00434083 · 1,200 participants · Start Jul 2004
Drug: sumatriptan; naproxen sodium · For: Migraine Headaches
Sites: Chapel Hill, North Carolina; Nashville, Tennessee
- Comparative Study of Oral Eletriptan (40mg and 80mg), Oral Sumatriptan (25mg and 50mg) and PlaceboPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT01986270 · 1,141 participants · Start Dec 1996 · Primary completion Jan 1998
Drug: Placebo; Eletriptan 40 mg and 3 more · For: Migraine With or Without Aura
- Dose Ranging Study of Rimegepant (BMS-927711) for the Acute Treatment of MigrainePivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01430442 · 1,026 participants · Start Oct 2011 · Primary completion May 2012
Drug: Rimegepant; Placebo and 1 more · For: Migraine; Acute Treatment of Migraine
Sites: Scottsdale, Arizona; Tempe, Arizona; San Francisco, California · 41 sites in all
- Eletriptan vs Sumatriptan: A Double-blind, Placebo-controlled, Multiple Migraine Attack StudyPivotal-lookingCompleted
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Pfizer (PFE)
NCT01986088 · 1,008 participants · Start Nov 1996 · Primary completion Jan 1998
Drug: Placebo; Eletriptan 40 mg and 3 more · For: Migraine With or Without Aura
- MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00897104 · 933 participants · Start Aug 1995 · Primary completion May 1996
Drug: rizatriptan benzoate (MK0462); Comparator: sumatriptan and 1 more · For: Migraine Headache
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective5,506
- headache3,209
- nausea2,893
- migraine2,820
- fatigue2,169
- pain2,016
- dizziness1,727
- vomiting1,649
- dyspnoea1,384
- off label use1,332
- anxiety1,310
- diarrhoea1,242
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 893 |
| 2005 | 1,256 |
| 2006 | 842 |
| 2007 | 851 |
| 2008 | 792 |
| 2009 | 865 |
| 2010 | 798 |
| 2011 | 904 |
| 2012 | 1,153 |
| 2013 | 1,087 |
| 2014 | 1,410 |
| 2015 | 2,197 |
| 2016 | 2,977 |
| 2017 | 2,171 |
| 2018 | 2,645 |
| 2019 | 3,028 |
| 2020 | 2,670 |
| 2021 | 2,165 |
| 2022 | 2,176 |
| 2023 | 2,174 |
| 2024 | 1,888 |
| 2025 | 1,858 |
| 2026 | 1,440 |
Recalls
1 FDA enforcement reports for this application.
Nov 6, 2013 · Class II · Terminated
Lack of Assurance of Sterility: A small number of pre-filled syringes may contain needles which protrude through the needle shield.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Imitrex (Sumatriptan)
2024 spending
$28K
Beneficiaries
24
36 claims
Per beneficiary
$1,184
$92.91 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $283,044 |
| 2021 | $221,580 |
| 2022 | $174,491 |
| 2023 | $232,297 |
| 2024 | $28,424 |
Part D: Imitrex* (Sumatriptan Succinate)
2024 spending
$5.1M
Beneficiaries
803
3,210 claims
Per beneficiary
$6,396
$169.56 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $6,791,519 |
| 2021 | $6,164,539 |
| 2022 | $5,295,110 |
| 2023 | $5,133,446 |
| 2024 | $5,135,591 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- 2025 guideline update to acute treatment of migraine for adults in the emergency department: The American Headache Society evidence assessment of parenteral pharmacotherapies.
Robblee J, Minen MT, Friedman BW, et al. · Headache 2026 · Systematic Review, Meta-Analysis
- Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.
Karlsson WK, Ostinelli EG, Zhuang ZA, et al. · BMJ 2024 · Systematic Review, Comparative Study
- Acute and preventive treatment of menstrual migraine: a meta-analysis.
Khoo CC, Liu CC, Lu M, et al. · J Headache Pain 2024 · Meta-Analysis
- The efficacy and safety of metoclopramide in relieving acute migraine attacks compared with other anti-migraine drugs: a systematic review and network meta-analysis of randomized controlled trials.
Abdelmonem H, Abdelhay HM, Abdelwadoud GT, et al. · BMC Neurol 2023 · Systematic Review, Network Meta-Analysis
- Sumatriptan.
Kaube H, May A, Pfaffenrath V · BMJ 1994 · Clinical Trial, Comment
- Comparative efficacy of different treatments for menstrual migraine: a systematic review and network meta-analysis.
Zhang H, Qi JZ, Zhang ZH · J Headache Pain 2023 · Systematic Review, Network Meta-Analysis
Sponsor: GSK · Also marketed as Imitrex
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.